Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis


Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis

Play all audios:


Plasminogen activator inhibitor 1 (PAI-1) has been found to be a bad prognostic factor in a number of tumours but the reason has not been fully explained. The human prostate cancer cell line


PC-3 and the human promyelocytic leukaemia cell line HL-60 were used in this study to determine the effect of PAI-1 on spontaneous and induced apoptosis in culture. Apoptosis was induced


with camptothecin or etoposide. Addition of a stable variant of PAI-1 or wild-type PAI-1 to these cells resulted in a significant inhibition of apoptosis. In contrast, both the latent form


of PAI-1 and the stable variant of PAI-1 inactivated by a specific neutralizing monoclonal antibody, or the stable variant of PAI-1 in a complex with recombinant urokinase did not inhibit


apoptosis. This indicated that the inhibitory activity of PAI-1 was required for its anti-apoptotic effect but the urokinase-type plasminogen activator receptor was not involved. These


findings provide an explanation for the bad prognostic correlation of high PAI-1 levels in tumours. The anti-apoptotic effect was also found in non-tumoural cells including human umbilical


vein endothelial cells and the benign human breast epithelial cell line MCF-10A, suggesting that this is a novel physiologic function of PAI-1. © 2000 Cancer Research Campaign


This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication


Alizadeh H, Ma D, Berman M, Bellingham D, Comerford SA, Gething MH, Sambrook JF and Niederkorn JY (1995) Tissue-type plasminogen activator-induced invasion and metastasis of murine


melanomas. Curr Eye Res 14: 449–458


From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this


license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/


Anyone you share the following link with will be able to read this content: